Guangzhou Baiyunshan Pharmaceutical Stock EBITDA
| GU5 Stock | EUR 2.14 0.04 1.90% |
Guangzhou Baiyunshan Pharmaceutical fundamentals help investors to digest information that contributes to Guangzhou Baiyunshan's financial success or failures. It also enables traders to predict the movement of Guangzhou Stock. The fundamental analysis module provides a way to measure Guangzhou Baiyunshan's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Guangzhou Baiyunshan stock.
Guangzhou |
Guangzhou Baiyunshan Pharmaceutical Company EBITDA Analysis
Guangzhou Baiyunshan's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Guangzhou Baiyunshan EBITDA | 5.46 B |
Most of Guangzhou Baiyunshan's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Guangzhou Baiyunshan Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Guangzhou Baiyunshan Pharmaceutical reported earnings before interest,tax, depreciation and amortization of 5.46 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The ebitda for all Germany stocks is 40.05% lower than that of the firm.
Guangzhou EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Guangzhou Baiyunshan's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Guangzhou Baiyunshan could also be used in its relative valuation, which is a method of valuing Guangzhou Baiyunshan by comparing valuation metrics of similar companies.Guangzhou Baiyunshan is rated below average in ebitda category among its peers.
Guangzhou Fundamentals
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0356 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 5.35 B | |||
| Shares Outstanding | 219.9 M | |||
| Shares Owned By Institutions | 34.00 % | |||
| Price To Earning | 8.09 X | |||
| Price To Book | 1.07 X | |||
| Price To Sales | 0.1 X | |||
| Revenue | 69.01 B | |||
| Gross Profit | 13.19 B | |||
| EBITDA | 5.46 B | |||
| Net Income | 3.72 B | |||
| Cash And Equivalents | 21.69 B | |||
| Cash Per Share | 13.34 X | |||
| Total Debt | 752.81 M | |||
| Debt To Equity | 0.36 % | |||
| Current Ratio | 1.64 X | |||
| Book Value Per Share | 19.33 X | |||
| Cash Flow From Operations | 5.67 B | |||
| Earnings Per Share | 0.33 X | |||
| Number Of Employees | 25.44 K | |||
| Beta | 0.7 | |||
| Market Capitalization | 6.7 B | |||
| Total Asset | 66.12 B | |||
| Z Score | 5.8 | |||
| Annual Yield | 0.04 % | |||
| Net Asset | 66.12 B | |||
| Last Dividend Paid | 0.69 |
About Guangzhou Baiyunshan Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Guangzhou Baiyunshan Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Guangzhou Baiyunshan using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Guangzhou Baiyunshan Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Guangzhou Stock
Guangzhou Baiyunshan financial ratios help investors to determine whether Guangzhou Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Guangzhou with respect to the benefits of owning Guangzhou Baiyunshan security.